Good morning. Finally some good news for Dame Emma Walmsley, the embattled chief executive of GlaxoSmithKline. An experimental Covid-19 vaccine developed by the FTSE 100 drugs giant in a joint venture with its French rival Sanofi showed a robust immune response in early-stage clinical trial results, Glaxo has announced this morning. The company said it planned to move to a phase III trial involving more than 35,000 adults within weeks, with the hope of the vaccine being approved and available by the end of the year. SponsoredRoger Connor, president of GSK vaccines, said: “These positive data show the potential of this protein-based adjuvanted vaccine candidate in the broader context of the pandemic, including the need to address variants and to provide for booster doses.”

Source: The Times May 17, 2021 08:03 UTC